Download Citation
Article Source:
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials
Sattar N,
Srinath R,
García-Pérez LE,
Lee CJ,
Karanikas CA,
et al.
(2026)
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.
PLOS ONE 21(8): e0345032.
https://doi.org/10.1371/journal.pone.0345032